Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT00413166 (Clinical Trial / Gentuzumab Ozogamicin)

Study Title
All-trans Retinoic Acid, and Arsenic +/- Gemtuzumab (NCT00413166)

Trial Description
The goal of this clinical research study is to learn if the combination of Arsenic Trioxide (ATO) (Trisenox®; Teva Pharmaceuticals) with All-Trans Retinoic Acid (ATRA) and possibly Idarubicin (Idamycin®; Pfitzer, Inc.) is effective in treating patients with newly-diagnosed Acute Promyelocytic Leukemia (APL)

This trial is sponsored by M.D. Anderson Cancer Center. [1]

Study Data

  • Condition: Acute Promyelocytic Leukemia (APL)
  • Interventions:
  • Phase: II
  • Estimated Enrollment: 80
  • Start: September 2006
  • Estimated Completion: September 2016
  • Last verified: October 2014

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: July 23, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar